Anaplastic Large Cell Lymphoma ALK-Positive — Treatment & Access

ALK-positive anaplastic large cell lymphoma (ALK+ ALCL) is a type of T-cell lymphoma defined by rearrangement of the ALK gene, most commonly the t(2;5) translocation producing the NPM1-ALK fusion protein. ALK positivity drives the lymphoma through constitutive kinase signalling and has a direct prognostic significance — ALK+ ALCL carries a substantially better prognosis than ALK-negative ALCL, which lacks this rearrangement. ALK positivity also provides a therapeutic target, enabling the use of ALK kinase inhibitors in relapsed/refractory disease.

ALK+ ALCL is one of the few aggressive lymphomas that disproportionately affects children, adolescents, and young adults — with a median age at diagnosis of around 20–30 years. The reason for this age distribution is not fully established but likely reflects the specific cellular origin and developmental context of the T-cell progenitor in which the ALK translocation arises. It is the most common aggressive T-cell lymphoma in paediatric patients, accounting for approximately 10–15% of all paediatric non-Hodgkin lymphomas.

Brentuximab vedotin (BV, Adcetris) is an antibody-drug conjugate that targets CD30 — an antigen uniformly expressed at high levels on the surface of all ALCL cells. BV links an anti-CD30 antibody to MMAE, a potent microtubule-disrupting toxin, which is delivered selectively to CD30-positive tumour cells. The ECHELON-2 trial showed that BV combined with CHP chemotherapy (BV-CHP) was superior to standard CHOP in CD30-positive peripheral T-cell lymphomas including ALK+ ALCL. BV-CHP is now the standard frontline treatment for fit adult patients.

Yes. Because the ALK kinase is the defining oncogenic driver of ALK+ ALCL, ALK inhibitors are rationally targeted therapies for this disease. Crizotinib has received FDA approval for ALK+ ALCL in paediatric patients and is used off-label in adults with relapsed/refractory disease at specialist centres. Multiple case reports and series document complete remissions. Next-generation ALK inhibitors (alectinib, lorlatinib) are used for crizotinib-resistant disease or CNS involvement. Access to these agents should be pursued through specialist lymphoma centres or compassionate use programmes.

Auto-SCT consolidation in first complete remission is generally recommended for high-risk ALK+ ALCL (advanced stage, high IPI, bone marrow involvement, or MRD positivity) but is not universally required for all patients. In low-risk, limited-stage ALK+ ALCL achieving deep MRD-negative remission with BV-CHP, some specialist centres consider observation without transplant. The decision is individualised based on risk profile, depth of remission, and MRD data, and is best made at a specialist PTCL transplant centre.

Minimal residual disease (MRD) monitoring uses highly sensitive molecular testing — typically RT-PCR for the NPM1-ALK fusion transcript — to detect very low levels of residual lymphoma after treatment that are below the threshold of standard imaging. MRD positivity after induction indicates a higher relapse risk even when imaging appears to show complete remission. MRD monitoring is well established in paediatric ALCL99 protocols and is increasingly used in adult clinical trials to guide treatment de-escalation in MRD-negative patients or intensification in MRD-positive patients.

Relapsed ALK+ ALCL — unlike most other PTCL — benefits from biologically rational salvage options beyond standard chemotherapy. ALK inhibitors (crizotinib, alectinib) are the most distinctive approach and are active in relapsed/refractory ALK+ ALCL. BV monotherapy has activity in patients not previously treated with BV. Conventional salvage chemotherapy (ICE, DHAP) aims to achieve remission bridging to allogeneic stem cell transplantation (allo-SCT) in CR2. Clinical trial enrolment — including next-generation ALK inhibitor combinations and CD30-directed CAR-T — is strongly encouraged for relapsed disease.

Paediatric ALK+ ALCL is managed with dedicated paediatric cooperative group protocols (such as ALCL99 or European ALCL-BV studies) that differ from adult approaches in several important ways: they incorporate MRD monitoring (NPM1-ALK RT-PCR) to guide treatment de-escalation or intensification; they use methotrexate pulses as part of the induction backbone; and they are administered by specialist paediatric haematology/oncology teams. Crizotinib has FDA approval specifically for paediatric ALK+ ALCL. Adults are treated with BV-CHP and managed by adult haematology/oncology teams. Adolescents may be treated in either setting, ideally with joint input from paediatric and adult specialists.

Yes. CancerFax supports patients of all ages with ALK-positive ALCL — from initial diagnosis through to relapsed or refractory disease. Our team reviews pathology reports and staging workups, facilitates expert second opinions from specialist lymphoma haematopathologists and oncologists, identifies BV-CHP access and ALK inhibitor eligibility, matches patients to clinical trials including paediatric cooperative group studies, and coordinates specialist referrals at leading lymphoma centres in India, China, and internationally. Please share your medical reports through the CancerFax portal or contact our team to begin.